source
- Novo Holdings invests €500 million in Europe-focused fund as Alnylam advances second obesity drug to clinicNovo Holdings, the investment arm of the Novo Nordisk Foundation, has committed €500 million to the Scaleup Europe Fund, a vehicle aimed at supporting European biotech scale‑ups. Alnylam Pharmaceu…
- Lilly and Boehringer cut German investments amid health-spending overhaulA proposed overhaul of Germany's health-insurance financing is sparking criticism from industry groups. Eli Lilly and Boehringer Ingelheim announced they will reduce their investment programmes in…